CNTB Connect Biopharma Holdings Ltd
Company Analysis
Latest News
🔴 Connect Biopharma is trading 5.6% down — cause remains unclear
Connect Biopharma is trading 5.6% down at $1.02 on September 29, 2026; the reason for the decline remains unclear. - No company-specific announcement or fresh...
🟢 Connect Biopharma is trading 7.4% up today in pre-market as biotech ETF XBI gains 2.61%
Connect Biopharma is trading at $1.15, up 7.41%, in a move that appears primarily sector-driven as biotechnology ETF XBI rises 2.61% pre-market. - The rebound...
🔴 Connect Biopharma Holdings Ltd is trading 10.70% down
CNTB is trading at $1.08, down 10.70%.
🔴 Connect Biopharma is trading 5.76% down today after Phase 2 asthma trial missed statistical significance
Connect Biopharma is trading at $1.15, down 5.76%, as investors continue reacting to the Phase 2 Seabreeze STAT asthma trial missing statistical significance...
🔴 Connect Biopharma is trading 5.3% down today after Phase 2 Seabreeze STAT asthma trial missed significance
Connect Biopharma is trading 5.3% down at $1.25 after its Phase 2 Seabreeze STAT asthma trial missed statistical significance. - The primary Day 28...
🔴 Connect Biopharma is trading 5.8% down in pre-market after Phase 2 asthma trial missed significance
Connect Biopharma is trading at $1.24, down -5.82%, after investor disappointment that its Phase 2 asthma trial missed statistical significance on the primary...
🔴 Connect Biopharma is trading 5.29% down in after-hours trading — catalyst remains unclear
Connect Biopharma is trading 5.29% down at $1.25 in after-hours trading, with the catalyst unclear. - It declined from the September 21 regular-session close...
🔴 Connect Biopharma Holdings Ltd is trading 5.43% down in pre-market
CNTB is trading at $1.22, down 5.43% in pre-market.
🔴 Connect Biopharma is trading 7% down in after-hours trading after its asthma trial missed the primary endpoint
Connect Biopharma is trading 7% down now at $1.20 after continued selling related to its September 15 asthma-trial readout: rademikibart improved FEV1 by 130...
🔴 Connect Biopharma is trading 9.3% down today after asthma trial missed its primary endpoint
Connect Biopharma is trading 9.3% down at $1.12 after its Phase 2 asthma trial missed its primary 28-day treatment-failure endpoint. - Continued selling...
Connect Biopharma's Asthma Drug Shows Promise but Misses the Mark — Is a $1.29 Stock Price a Second Chance or a Value Trap?
Shares of Connect Biopharma whipsawed this week, plunging 32.17% on September 15 before rebounding 10.3% to $1.29 the following session, as investors picked...
🟢 Connect Biopharma is trading 10.26% up today after mixed September 15 Phase 2 asthma results
Connect Biopharma is trading 10.26% up at $1.29 as investors reassess mixed September 15 Phase 2 asthma results after the stock fell 32.17% to $1.17. -...
🟢 Connect Biopharma is trading 5.64% up today after reassessment of Phase 2 asthma data
Connect Biopharma is trading 5.64% up now at $1.24, as investors reassess September 15 Phase 2 asthma data after the stock fell 32.17% to $1.17. -...
Connect Biopharma Reports Phase 2 Asthma Trial Data for Rademikibart, Meeting Key Secondary Endpoint
Connect Biopharma Holdings Limited announced topline results from its global Phase 2 study of rademikibart for treating acute asthma exacerbations. The study...
🔴 Connect Biopharma is trading 29.35% down today
Connect Biopharma is trading 29.35% down now at $1.22, after closing at $1.73 on September 14, 2026; no clear company-specific announcement has been identified...
🔴 Connect Biopharma is trading 39% down in pre-market
Connect Biopharma is trading at $1.06, down 38.7% after closing at $1.73 on September 14, 2026; no clear company-specific announcement explains the September...
🔴 Connect Biopharma is trading 46.2% down in pre-market; no company-specific announcement identified
Connect Biopharma is trading 46.2% down now at $0.93 after closing at $1.73 on September 14, 2026; no new company-specific announcement was identified to...
🔴 Connect Biopharma is trading 20.62% down today amid broader risk-off conditions
Connect Biopharma is trading at $1.62, down -20.62%, amid broader risk-off conditions and weakness in smaller biotech shares. - The Nasdaq Composite is down...
🔴 Connect Biopharma is trading 11.27% down in pre-market as Nasdaq Composite falls 1.73%
Connect Biopharma is trading 11.27% down at $1.81 after broad pre-market weakness. - The Nasdaq Composite is down 1.73%, while the S&P 500 is down 0.76%. - No...
🔴 Connect Biopharma is trading 7.67% down in pre-market as Nasdaq Composite falls 1.54%
Connect Biopharma is trading 7.67% down at $1.88 after broader pre-market weakness. - The Nasdaq Composite is down 1.54%, with no new company-specific...